

IN THE CLAIMS:

Please amend claims 5 and 10 as follows:

a2 5. (Amended) The polynucleotide of any one of claims 1-4 which is DNA or RNA.

a3 10. (Amended) IGS1 receptor membrane preparation derived from a cell according to any one of claims 7-9.

REMARKS

The presentation of a clean set of claims is permitted under new rule 37 C.F.R. §1.121 (c)(3), effective November 7, 2000. An amended form of claims 5 and 10 is attached for the Examiner's convenience pursuant to new rule 37 C.F.R. §1.21(c)(1)(ii), to eliminate improper multiple claim dependency. No new matter has been introduced by these amendments.


The examiner is respectfully requested to consider the above preliminary amendment prior to examination of the application.

If there are any fees due in connection with the filing of this Amendment, please charge the fees to Deposit Account No. 06-0916. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our deposit account.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: January 11, 2002

By: 
Ernest F. Chapman
Reg. No. 25,961

EFC/FPD/dvz

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com